Treatment with 4-1BB Aptamer-CD25 siRNA Conjugates Potentiates Vaccine-Induced Antitumor Immunity in the 4T1 Breast Carcinoma Model
BALB/c mice (5 mice/group) were implanted with 4T1 tumor cells. 7 days later, they were vaccinated with irradiated B7-1 and MHC class II-expressing 4T1 cells (A) or irradiated stereo tactically with 12 Gy at the site of tumor implantation (B). Vaccination was on days 10 and 13. On days 8, 11, and 14 after tumor implantation in vaccination experiments or days 7, 9, and 11 after radiation, mice were injected intravenously with 4-1BB aptamer-CD25 siRNA or 4-1BB aptamer-luc siRNA conjugates as indicated (5 mice/group; vaccination experiment, n = 3; irradiation experiment n = 2).